Key result
Endomyocardial biopsy confirms eosinophilic myocarditis, which responds primarily to etiology-tailored immunosuppression.
Answers are grounded in this paper and cite their sources.
This narrative review synthesizes the heterogeneous etiologies, diagnostic workup (highlighting CMR for noninvasive tissue characterization and endomyocardial biopsy for definitive diagnosis), and etiology-directed immunosuppressive and targeted therapies for eosinophilic myocarditis.
Eosinophilic myocarditis (EM) represents a rare form of myocardial inflammation with very heterogeneous aetiology. In developed countries, the most prevalent causes of EM are hypersensitivity or allergic reactions, as well as hematological diseases leading to eosinophilia. The disease may have a variable clinical presentation, ranging from asymptomatic forms to life-threatening conditions. Most patients with EM have marked eosinophilia in peripheral blood. Endomyocardial biopsy needs to be performed in most cases in order to establish a definitive diagnosis of EM. The therapy depends on the underlying aetiology. Immunosuppressive therapy represents the treatment mainstay in the majority of EM forms.
No takes yet. Share an insight, caveat, or question.
Kuchynka et al. (2016) conducted a review in Eosinophilic myocarditis. Immunosuppressive therapy (corticosteroids, cyclophosphamide, azathioprine), imatinib, mepolizumab, and endomyocardial biopsy/CMR diagnosis was evaluated. Eosinophilic myocarditis requires endomyocardial biopsy for definitive diagnosis and is primarily treated with immunosuppressive therapy tailored to the underlying etiology.
Synapse has enriched 10 related papers. Consider them for comparative context: